ACTR-50. EFFECT OF CONCURRENT AND ADJUVANT TEMOZOLOMIDE ON SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED GRADE III GLIOMAS WITHOUT 1p/19q CO-DELETION: A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY (INTERIM RESULTS FROM THE KNOG-1101 STUDY)

Lignende værker

• Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study)
  af: Hwang, Kihwan, et al.
  Udgivet: (2020)
• ACTR-38. A SINGLE CENTER STUDY: LONG-TERM OUTCOMES OF COMBINED CHEMORADIATION THERAPY WITH TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA IN KOREAN PATIENT
  af: Go, Kyeong-O, et al.
  Udgivet: (2019)
• Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
  af: Kim, Byung Sup, et al.
  Udgivet: (2017)
• Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea
  af: Bae, So Hyun, et al.
  Udgivet: (2014)
• The Combination PARP Inhibitor Olaparib With Temozolomide in an Experimental Glioblastoma Model
  af: HWANG, KIHWAN, et al.
  Udgivet: (2021)